Difference between revisions of "Work Product for Review"
| Line 1: | Line 1: | ||
==<font color=red> Public Comment on QIBA Profiles and Protocols</font>== | ==<font color=red> Public Comment on QIBA Profiles and Protocols</font>== | ||
QIBA Profiles are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details. | QIBA Profiles are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details. | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
The [[Committees|QIBA Biomarker Committees]] who develop QIBA Profiles and Protocols consider all comments submitted, and where appropriate, post responses. | The [[Committees|QIBA Biomarker Committees]] who develop QIBA Profiles and Protocols consider all comments submitted, and where appropriate, post responses. | ||
| − | |||
| − | |||
==Directions for Comment Submission== | ==Directions for Comment Submission== | ||
Revision as of 21:49, 9 February 2017
Public Comment on QIBA Profiles and Protocols
QIBA Profiles are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.
The QIBA Biomarker Committees who develop QIBA Profiles and Protocols consider all comments submitted, and where appropriate, post responses.
Directions for Comment Submission
Use the public comment form to submit comments concerning QIBA Profiles/Protocols to the QIBA Biomarker Committees. Documents currently in the Public Comment phase are listed below. Submitted comments will be considered for the revised versions of these documents.
- If you have general comments about the Profile/Protocol concept, structure, process, etc., please e-mail those directly to (Susan Weinmann)
Instructions:
1. Visit the public comment form
2. Select and download Profiles or Protocols for review (see link below).
- Profile:
- Protocol:
3. Designate Section or Line Number for each comment (or designate as "general").
4. Specify the Issue concisely and provide any new or replacement text in the Proposal section.
5. Designate the Priority of each comment as High (H), Medium (M), or Low (L)
- H: Important issue where there is a major issue to be resolved; requires discussion and debate.
- M: Medium issue or clarification. Requires discussion, but should not lead to long debate.
- L: Typo or other minor classification that an editor can manage; requires no group discussion.
6. Comments are due by date listed next to each document.
QIBA Profiles and Protocols for Reference
- QIBA Profile: QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 The Public Comment period ends February 1, 2017.
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 The Public Comment period has closed
- QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016 The Public Comment period has closed
- QIBA Spreadsheet: Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016 The Public Comment period has closed